Mohammad H Abu-Arja

ORCID: 0000-0003-4606-2269
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Glioma Diagnosis and Treatment
  • Brain Metastases and Treatment
  • Neuroblastoma Research and Treatments
  • Testicular diseases and treatments
  • Management of metastatic bone disease
  • Chromatin Remodeling and Cancer
  • Ocular Oncology and Treatments
  • Vascular Malformations Diagnosis and Treatment
  • Cerebrospinal fluid and hydrocephalus
  • Pregnancy and preeclampsia studies
  • Meningioma and schwannoma management
  • Hearing, Cochlea, Tinnitus, Genetics
  • Immune Cell Function and Interaction
  • Childhood Cancer Survivors' Quality of Life
  • Telemedicine and Telehealth Implementation
  • Social Media in Health Education
  • Adrenal and Paraganglionic Tumors
  • Congenital Diaphragmatic Hernia Studies
  • Cancer Mechanisms and Therapy
  • Neonatal Respiratory Health Research
  • Radiation Dose and Imaging
  • CNS Lymphoma Diagnosis and Treatment
  • Teratomas and Epidermoid Cysts
  • Nanowire Synthesis and Applications
  • Genetic and Kidney Cyst Diseases

Texas Children's Hospital
2021-2025

Baylor College of Medicine
2021-2025

Children's Cancer Center
2021-2025

Houston Methodist
2025

Methodist Hospital
2025

Cornell University
2020-2021

Nationwide Children's Hospital
2017-2021

The Ohio State University
2018-2021

NewYork–Presbyterian Brooklyn Methodist Hospital
2020-2021

Chimeric antigen receptor T cells (CART) targeting CD19 through CD28.ζ signaling induce rapid lysis of leukemic blasts, contrasting with persistent tumor control exhibited by 4-1BB.ζ-CART. We reasoned that molecular dynamics at the CART immune synapse (CARIS) could explain differences in their rejection kinetics. observed CD28.ζ-CART engaged brief highly lethal CARIS and mastered serial killing, whereas 4-1BB.ζ-CART formed lengthy relied on robust expansion cooperative killing. analyzed...

10.1126/sciadv.adq8114 article EN cc-by-nc Science Advances 2025-01-10

Little is known about the effects of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and disease 2019 (COVID-19) on pregnant mothers their infants. Moreover, there no definitive evidence that SARS CoV- can be vertically transmitted from an infected mother to unborn fetus.

10.1093/jpids/piaa109 article EN other-oa Journal of the Pediatric Infectious Diseases Society 2020-09-01

Abstract Background We report the outcomes of patients with pineoblastoma and trilateral retinoblastoma syndrome enrolled on Head Start (HS) I‐III trials. Methods Twenty‐three children were prospectively between 1991 2009. Treatment included maximal surgical resection followed by five cycles intensive chemotherapy consolidation marrow‐ablative autologous hematopoietic cell rescue (HDCx/AuHCR). Irradiation following was reserved for over six years age or those residual tumor at end induction....

10.1002/pbc.28252 article EN Pediatric Blood & Cancer 2020-03-18

Hearing loss (HL) is associated with worse neurocognitive outcomes among patients medulloblastoma. We aimed to identify risk factors severe HL and evaluate the generalizability of a published calculator treated passive scattering proton therapy (PSPT) cisplatin. identified aged 3-21 years who were at our centers between 2007 2022. Audiograms graded using International Society Pediatric Oncology (SIOP) Boston scale. Time grades 3-4 was evaluated Kaplan-Meier multivariable Cox models estimate...

10.1093/neuonc/noae114 article EN other-oa Neuro-Oncology 2024-06-24

PURPOSE Pediatric neuro-oncology resources are mostly unknown in Chile. We report the human and material available Chilean hospitals providing pediatric services. METHODS A cross-sectional survey was distributed to 17 services (Programa Infantil Nacional de Drogas Antineoplásicas [PINDA] hospitals, 11; private, 6). RESULTS Response rate 71% (PINDA, 8; 4). were mainly provided within general (67%). Registries for CNS tumors chemotherapy-related toxicities 100% 67% of respectively. treated by...

10.1200/go.20.00430 article EN cc-by-nc-nd JCO Global Oncology 2021-03-31

Abstract Background Central nervous system (CNS) germinomas are treatment‐sensitive tumors with excellent survival outcomes. Current treatment strategies combine chemotherapy radiotherapy (RT) in order to reduce the field and dose of RT. Germinomas originating basal ganglia/thalamus (BGTGs) have proven challenging treat given their rarity poorly defined imaging characteristics. Craniospinal (CSI), whole brain (WBI), ventricle (WVI), focal RT all been utilized; however, best strategy remains...

10.1002/pbc.29172 article EN Pediatric Blood & Cancer 2021-06-14

Abstract BACKGROUND Relapsed central nervous system germinomas are rare with no universal agreement regarding management. We explored the prognostic factors that may impact treatment of patients relapsed CNS germinoma. METHODS collected data on relapsed/progressive from nine large international sites. Data was summarized using descriptive statistics. Overall survival (OS) evaluated Kaplan-Meier and Fischer’s exact test to estimate odds ratios (OR) 95% confidence intervals (CI). RESULTS...

10.1093/neuonc/noae064.284 article EN cc-by-nc Neuro-Oncology 2024-06-18

Abstract BACKGROUND Patients with relapsed/refractory central nervous system (CNS) non-germinomatous germ cell tumors (NGGCTs) have poor prognosis. We explored prognostic factors to guide the management of these patients. METHODS performed a multinational retrospective study CNS NGGCTs. Data were summarized using standard descriptive statistics. Overall survival (OS) was evaluated Kaplan-Meier and Fisher’s exact test estimate odds ratios (OR) 95% confidence intervals (CI). RESULTS identified...

10.1093/neuonc/noae064.276 article EN cc-by-nc Neuro-Oncology 2024-06-18

Abstract BACKGROUND Primary intracranial germ cell tumors (GCTs) are rare heterogeneous tumors; germinoma accounts for two-thirds of cases. While neoadjuvant chemotherapy followed by response-based reduced radiotherapy dose and field is the established approach managing localized CNS germinomas, controversy persists regarding treatment primary metastatic disease. Additionally, limited research exists on utilization in germinoma. METHODS A retrospective multi-institutional analysis was...

10.1093/neuonc/noae064.260 article EN cc-by-nc Neuro-Oncology 2024-06-18

Abstract Neonatal and infant aortic thrombosis is a rare albeit life‐threatening thrombotic event, particularly seen in premature infants with an arterial catheter place. We describe our institutional experience approach to the management of 11 occlusive or nearly thrombosis. observed at least partial thrombus resolution all patients. Complications related included minor bleeding two children receiving thrombolytic therapy, major events anticoagulation alone. Our adds growing body evidence...

10.1002/pbc.31283 article EN Pediatric Blood & Cancer 2024-08-16

The LATB is a weekly teleconference operating over 3.5 years connecting pediatric neuro-oncologists from high-income countries with subspecialists 20 Latin-American countries. This survey explored the participants’ experience utilizing this resource. A web-based questionnaire was distributed to 159 participants through email and www.Cure4Kids.org. Ninety-five respondents (60%) all participating completed survey. Sixty-one reported frequent-attendance (≥ 1 per month), 23 infrequent-attendance...

10.1093/neuonc/noy059.082 article EN Neuro-Oncology 2018-06-01

Abstract BACKGROUND Patients with relapsed CNS NGGCTs experience poor outcomes. Our aim to explore prognostic factors that may guide future clinical trials. METHODS A review of trials included patients was performed. RESULTS Seventy-four were identified; only 14 (19%) long-term survivors. who >24 months after initial diagnosis had a survival rate 47% compared 15% in <24 (p= 0.015). Patient serum/cerebrospinal fluid (CSF) alpha-fetoprotein (AFP) level <25 ng/ml at relapse...

10.1093/neuonc/noaa222.258 article EN cc-by-nc Neuro-Oncology 2020-12-01

In the context of an evolving understanding early T-cell precursor (ETP) lymphoma and leukemia, we present a case concurrent lymphoblastic ETP in adolescent female. To our knowledge, this represents first reported both as distinct conjoined components same neoplasm. As exception to current literature, patient had strictly lymphomatous component with no leukemic manifestation. Her remained viable following induction, supporting resistance chemotherapy. The remains remission 4 years...

10.1097/mph.0000000000002257 article EN Journal of Pediatric Hematology/Oncology 2021-07-22

Abstract BACKGROUND Relapsed central nervous system (CNS) germinomas are rare with no universal agreement regarding management. We explore prognostic factors that may impact the treatment of patients relapsed CNS germinoma. METHODS An international multi-institutional retrospective study relapsed/progressive was conducted. Data summarized using descriptive statistics. Overall survival (OS) evaluated Kaplan-Meier and Fischer’s exact test to estimate odds ratios (OR) 95% confidence intervals...

10.1093/neuonc/noad073.137 article EN cc-by-nc Neuro-Oncology 2023-06-01

Abstract PURPOSE Patients with relapsed/refractory central nervous system (CNS) non-germinomatous germ cell tumors (NGGCTs) have poor outcomes. There is no universal agreement on managing these patients secondary to the rarity of disease and lack prospective trials. We aim explore prognostic factors that may help guide management CNS NGGCTs. METHODS performed a multinational retrospective study summarized all data using standard descriptive statistics. Overall survival (OS) was evaluated...

10.1093/neuonc/noad073.136 article EN cc-by-nc Neuro-Oncology 2023-06-01

Abstract PURPOSE To evaluate the incidence and risk factors for hearing loss (HL) among children with medulloblastoma treated proton irradiation cisplatin. METHODS We identified ≥3 years of age at Texas Children’s Hospital between 2007-2022. Audiograms were graded using International Society Pediatric Oncology-Boston scale (SIOP-Boston). Time to grade HL was evaluated Kaplan-Meier multivariable Cox models estimate hazard ratios (HR) 95% confidence intervals (CI). RESULTS Seventy-eight...

10.1093/neuonc/noad073.297 article EN cc-by-nc Neuro-Oncology 2023-06-01
Coming Soon ...